StocktoriaChina SXT Pharmaceuticals, Inc. SXTC
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
2.19
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $1.7M | $1.9M | $2.0M | $2.6M | $4.8M |
| Gross profit | $367,427 | $553,971 | $426,271 | $1.3M | $2.8M |
| Operating income | -$2.7M | -$2.5M | -$5.6M | -$5.2M | -$2.2M |
| Net income | -$3.3M | -$3.1M | -$5.9M | -$5.7M | -$2.7M |
| Operating cash flow | -$2.3M | -$1.9M | -$80,757 | $268,293 | -$1.3M |
| Total assets | $21.7M | $23.1M | $29.6M | $33.5M | $34.5M |
| Total liabilities | $6.2M | $9.2M | $14.9M | $17.1M | $18.6M |
| Shareholders' equity | $15.4M | $13.9M | $14.7M | $16.1M | $16.0M |
| Ratios | |||||
| Gross margin | 21.1% | 28.7% | 21.6% | 48.1% | 59.4% |
| Operating margin | -154.0% | -130.4% | -284.4% | -199.4% | -46.0% |
| Net margin | -189.8% | -160.7% | -301.0% | -220.4% | -57.5% |
| Return on assets | -15.2% | -13.4% | -20.1% | -17.1% | -8.0% |
| Return on equity | -21.4% | -22.2% | -40.4% | -35.7% | -17.2% |
| Debt / equity | 0.01× | 0.01× | 0.01× | — | 0.00× |
| Current ratio | 3.54 | 1.60 | 1.35 | 1.31 | 1.25 |
| Revenue growth | -9.7% | -2.2% | -24.2% | -45.5% | -7.5% |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 2.19 (grey)
- Working capital / assets 0.706
- Retained earnings / assets -1.293
- EBIT / assets -0.124
- Equity / liabilities 2.481
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001723980 · as of 2025-03-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.